|
|
Blood, 15 May 2006, Vol. 107, No. 10, pp. 4071-4079.
Prepublished online as a Blood First Edition Paper on January 17, 2006; DOI 10.1182/blood-2005-08-3153.
Previous Article | Next Article 
Submitted August 5, 2005
Accepted January 7, 2006
The FIP1L1-PDGFR fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease
YOSHIYUKI YAMADA, MARC E ROTHENBERG, ANDREW W LEE, HIROKO SAITO AKEI, ERIC B BRANDT, DAVID A WILLIAMS, and JOSE A CANCELAS*
Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
Division of Experimental Hematology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
Division of Experimental Hematology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Hoxworth Blood Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
* Corresponding author; email: jose.cancelas{at}chmcc.org.
Dysregulated tyrosine kinase activity by the Fip-1-like 1 (FIP1L1)-platelet derived growth factor receptor alpha (PDGFR ) (F/P) fusion gene has been identified as a cause of clonal hypereosinophilic syndrome (HES), called F/P-positive chronic eosinophilic leukemia (CEL) in human. However, transplantation of F/P-transduced hematopoietic stem cells/progenitors (F/P+ HSC/P) into mice results in chronic myelogenous leukemia-like disease, which does not resemble HES. Because a subgroup of patients with HES show T-cell dependent interleukin-5 (IL-5) overexpression, we determined if expression of the F/P fusion gene in the presence of transgenic T-cell IL-5 overexpression in mice induces HES-like disease. Mice transplanted with CD2-IL-5 transgenic F/P+ HSC/P (IL-5Tg-F/P) developed intense leukocytosis, strikingly high eosinophilia and eosinophilic infiltration of non-hematopoietic as well as hematopoietic tissues, a phenotype resembling human HES. The disease phenotype was transferable to secondary recipients transplanted at a high cell dose, suggesting involvement of a short-term repopulating stem cell or an early myeloid progenitor. Induction of significant eosinophilia was specific for F/P since expression of another fusion oncogene, p210-BCR/ABL in the presence of IL-5 overexpression was characterized by a significantly lower eosinophilia than IL-5Tg-F/P recipients. These results suggest that F/P is not sufficient to induce a HES/CEL-like disease but requires a second event associated with IL-5 overexpression.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. C. Kottyan, A. R. Collier, K. H. Cao, K. A. Niese, M. Hedgebeth, C. G. Radu, O. N. Witte, G. K. Khurana Hershey, M. E. Rothenberg, and N. Zimmermann
Eosinophil viability is increased by acidic pH in a cAMP- and GPR65-dependent manner
Blood,
September 24, 2009;
114(13):
2774 - 2782.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Fukushima, I. Matsumura, S. Ezoe, M. Tokunaga, M. Yasumi, Y. Satoh, H. Shibayama, H. Tanaka, A. Iwama, and Y. Kanakura
FIP1L1-PDGFR{alpha} Imposes Eosinophil Lineage Commitment on Hematopoietic Stem/Progenitor Cells
J. Biol. Chem.,
March 20, 2009;
284(12):
7719 - 7732.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Cools
FIP1L1/PDGFR{alpha}'s Kit to stimulate mast cells
Blood,
September 15, 2008;
112(6):
2179 - 2179.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Yamada, A. Sanchez-Aguilera, E. B. Brandt, M. McBride, N. J. H. Al-Moamen, F. D. Finkelman, D. A. Williams, J. A. Cancelas, and M. E. Rothenberg
FIP1L1/PDGFR{alpha} synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome
Blood,
September 15, 2008;
112(6):
2500 - 2507.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Buitenhuis, L. P. Verhagen, J. Cools, and P. J. Coffer
Molecular Mechanisms Underlying FIP1L1-PDGFRA-Mediated Myeloproliferation
Cancer Res.,
April 15, 2007;
67(8):
3759 - 3766.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|